Replies to post #6 on Nkarta Inc (NKTX)

[jondoeuk]

For the allo CAR-T product ('personalised' for certain types) I would like them to insert the CAR(s) into the TRAC locus [1], stop rejection [2], use both CD4/CD8 [3] (of the naive plus (stem) central memory phenotype [4-6]), add a cytokine signal [7], screen donors [8], and make sure the cells are polyfunctional [9] for a start.

In addition, make sure the knockouts are designed to try and overcome the TMEs.

Refs:
1 https://www.nature.com/articles/nature21405
2 https://www.sciencedirect.com/science/article/pii/S0065277615000310
3 https://www.nature.com/articles/leu2015247
4 https://www.nature.com/articles/nm.4241
5 https://www.pnas.org/content/106/41/17469
6 https://www.pnas.org/content/102/27/9571
7 https://www.nature.com/articles/nm.4478
8 https://cancerres.aacrjournals.org/content/80/16_Supplement/879
9 https://ashpublications.org/blood/article/132/8/804/39474/Preinfusion-polyfunctional-anti-CD19-chimeric